Skip to main navigation Skip to search Skip to main content

Serum from patients with asthma potentiates macrophage phagocytosis and human mesenchymal stromal cell therapy in experimental allergic asthma

  • Soraia Abreu
  • , Leonardo Alves
  • , Luiza Carvalho
  • , Debora Xisto
  • , Natália Blanco
  • , Lígia Castro
  • , Priscilla Olsen
  • , Jose Roberto Lapa e Silva
  • , Marcelo Marcos Morales
  • , Miquéias Lopes-Pacheco
  • , Daniel Weiss
  • , Patricia Rieken Macedo Rocco*
  • *Corresponding author for this work
  • Museu Nacional/UFRJ
  • National Institute of Science and Technology for Regenerative Medicine
  • University of Lisbon
  • University of Vermont

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Background/Aims: Although several studies have demonstrated that mesenchymal stromal cells (MSCs) exhibit beneficial immunomodulatory properties in preclinical models of allergic asthma, effects on airway remodeling have been controversial. Recent evidence has shown that MSCs modify their in vivo immunomodulatory actions depending on the specific inflammatory environment encountered. Accordingly, we assessed whether the therapeutic properties of human mesenchymal stromal cells (hMSCs) could be potentiated by conditioning these cells with serum (hMSC-serum) obtained from patients with asthma and then transplanted in an experimental model of house dust mite (HDM)-induced allergic asthma. Methods: hMSC and hMSC-serum were administered intratracheally 24 h after the final HDM challenge. hMSC viability and inflammatory mediator production, lung mechanics and histology, bronchoalveolar lavage fluid (BALF) cellularity and biomarker levels, mitochondrial structure and function as well as macrophage polarization and phagocytic capacity were assessed. Results: Serum preconditioning led to: (i) increased hMSC apoptosis and expression of transforming growth factor-β, interleukin (IL)-10, tumor necrosis factor-α–stimulated gene 6 protein and indoleamine 2,3-dioxygenase-1; (ii) fission and reduction of the intrinsic respiratory capacity of mitochondria; and (iii) polarization of macrophages to M2 phenotype, which may be associated with a greater percentage of hMSCs phagocytosed by macrophages. Compared with mice receiving hMSCs, administration of hMSC-serum led to further reduction of collagen fiber content, eotaxin levels, total and differential cellularity and increased IL-10 levels in BALF, improving lung mechanics. hMSC-serum promoted greater M2 macrophage polarization as well as macrophage phagocytosis, mainly of apoptotic hMSCs. Conclusions: Serum from patients with asthma led to a greater percentage of hMSCs phagocytosed by macrophages and triggered immunomodulatory responses, resulting in further reductions in both inflammation and remodeling compared with non-preconditioned hMSCs.

Original languageEnglish
Pages (from-to)967-976
Number of pages10
JournalCytotherapy
Volume25
Issue number9
DOIs
StatePublished - Sep 2023
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • human bone marrow stromal cells
  • immunomodulation
  • inflammation
  • macrophage phagocytosis
  • macrophage polarization
  • remodeling

Fingerprint

Dive into the research topics of 'Serum from patients with asthma potentiates macrophage phagocytosis and human mesenchymal stromal cell therapy in experimental allergic asthma'. Together they form a unique fingerprint.

Cite this